Another thing is that many inexperienced folks focus on our share price. What should be tracked is our diluted market cap. This has fallen too but not as far. And its fall likely reflects the delays and uncertainties around this very young, very small, very risky biotech. At this point, it 'appears' the company can possibly lose its primary source of capital (Aspire). While this is not strictly true (we can find another financier, or issue directly, if we fail to get a B partner or P doesn't pan out), the market is not confident.
Regardless: if a company is issuing lots of shares or warrants, consider the diluted market cap, not the share price.
News 
Market Data 
Discover 
AI
